Should You Buy Jazz Pharmaceuticals Stock For Its Cash?

Nov 20, 2026
should-you-buy-jazz-pharmaceuticals-stock-for-its-cash?

Image from Pixabay

Today’s big story: Will 2027 Be A 2022 Repeat For Stocks?

Jazz Pharmaceuticals (JAZZ) produced $1.41 billion of free cash flow over the past twelve months. That equals 9.2% of its market value, against 4.4% for the median S&P 500 company. A yield that high marks one of two things: a business on sale, or one the market expects to shrink. Jazz also owes $5.65 billion, so not all of that cash is the owners’ to keep. So what does that cash give you as an owner?

What Does Jazz’s Cash Yield Give You?

As a shareholder, you own a slice of the free cash Jazz produces, whether or not it is paid out. That works the same way as your slice of its profit: cash that stays in the company still belongs to its owners. When the market recognizes that cash, the share price tends to follow, and more so when the cash is growing. That is why a yield about twice the median company’s deserves a look.

Jazz’s debt minus its cash, known as net debt, was $2.79 billion at the end of September 2026, equaling 18.2% of its market value. Measured against the company’s whole value, debt included, Jazz’s free cash flow yield is 7.8%.

How Jazz Makes Its Cash

Jazz focuses on drugs for rare diseases, and each sale costs it little to make. Its gross margin was 89.1% over the past twelve months. Sales of its sleep drug, Xywav, grew 12% to $483 million in the third quarter of 2026.

Jazz Pharmaceuticals’ sleep drug Xywav alone brought in $483 million in the third quarter of 2026. If Jazz is a big part of your savings, your money is riding on a few drugs keeping their sales. Our partner advisory firm will take your question on a free 30-minute call, by phone or video, with no obligation. Book a free call.

Jazz also keeps most of its operating cash after capital spending. It put 16.5% of its cash from operations into capital spending over the past twelve months. Its free cash flow came to 30.0% of revenue.

That cash has grown. Jazz’s free cash flow over the past twelve months was up from $1.24 billion a year earlier. Measured over twelve months at each of the last 13 quarter ends, its free cash flow stayed above zero, between $0.87 billion and $1.49 billion.

Jazz covers its interest with room to spare. Its operating income was 6.8 times its interest expense over the past twelve months. In the third quarter, Jazz issued $1.25 billion of convertible notes, debt that can turn into shares, management said. It also spent $820 million to buy Actio Biosciences, which adds an epilepsy drug in testing.

What Could Shrink Jazz’s Cash?

Leave a comment